Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07052942 · ClinicalTrials.gov registry record · Phase 4
Individualizing Treatment for Asthma in Primary Care (Full Study)
A Phase 4 study of Asthma and Asthma Attack, sponsored by DARTNet Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3,200
- Enrollment target
- 13
- Study locations
NCT07052942: Recruiting Phase 4 study of Asthma and Asthma Attack, sponsored by DARTNet Institute.
NCT07052942 is a Phase 4 study of Asthma and Asthma Attack that is actively recruiting participants, run by DARTNet Institute. The registered enrollment target is 3,200 participants, above the 1,555-participant average among 374 other Asthma trials with a reported enrollment target (106% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07052942, a Phase 4 study of Asthma and Asthma Attack, is actively recruiting participants, sponsored by DARTNet Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,200 participants
- Enrollment target
- 13
- Study locations
Study Summary
While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.
Primary Outcome
The primary outcome, the rate of asthma exacerbations per year, is defined as the number of exacerbations, emergency room visits, or hospitalizations requiring oral or parenteral corticosteroids, per patient per year, monthly through study completion.
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Inhaled corticosteroid (ICS)
- OTHER Asthma Symptom Monitoring Web-based Application
Study Locations (13)
Colorado
- DARTNet Institute - Aurora
- University Colorado-Denver - Aurora
North Carolina
- University North Carolina - Chapel Hill
- Atrium Health - Charlotte
Texas
- JPS Health Network - Fort Worth
- Kelsey Research Foundation - Houston
Florida
- AdventHealth - Orlando
Kansas
- University of Kansas - Kansas City
Massachusetts
- Reliant Medical Group - Worcester
Missouri
- University of Missouri - Columbia
New Jersey
- Rutgers Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2029-11-15 |
| Phase | Phase 4 |
What NCT07052942 shows while recruiting
NCT07052942 is an interventional study that assigns participants to a tested intervention. Its 3,200 participants enrollment target places it among the larger protocols in the corpus, above the 1,555-participant average among 374 other Asthma trials with a reported enrollment target (106% higher).
The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Azithromycin is the first listed.
NCT07052942 lists 13 locations in 10 states (Colorado, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT07052942 about?
NCT07052942 is a clinical study titled "Individualizing Treatment for Asthma in Primary Care (Full Study)". While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long ...
What is the current status of trial NCT07052942?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,200 participants. The study started on 2025-08-01. Estimated completion is 2029-11-15.
What conditions does trial NCT07052942 study?
This clinical trial studies the following conditions: Asthma, Asthma Attack, Asthma Exacerbations.
What interventions are being tested in trial NCT07052942?
The interventions under investigation include: Azithromycin (DRUG), Inhaled corticosteroid (ICS) (DRUG), Asthma Symptom Monitoring Web-based Application (OTHER).
Who is sponsoring clinical trial NCT07052942?
This trial is sponsored by DARTNet Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07052942 being conducted?
This trial has 13 study locations across Colorado, Florida, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07052942's enrollment target sits among peer trials
3,200 15th of 374 higher than 360 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
- NCT06042543 · 3,200 participants · NA
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI